Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAB BioAtla	$0.42 -5.3%	$0.38	$0.24 ▼ $2.53	$24.66M	0.9	711,353 shs	482,742 shs
OTLC Oncotelic Therapeutics	$0.05 +13.7%	$0.05	$0.02 ▼ $0.07	$21.71M	-0.9	110,802 shs	9,540 shs
RLMD Relmada Therapeutics	$0.77 +15.6%	$0.62	$0.24 ▼ $3.98	$25.56M	0.66	1.11 million shs	1.03 million shs
ULUR ULURU		$0.00	$0.10 ▼ $0.79	$5.35M	-3.13	6,691 shs	N/A

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAB BioAtla	+9.89%	+19.05%	+26.21%	+14.27%	-75.04%
OTLC Oncotelic Therapeutics	-6.99%	-8.63%	-8.27%	-28.31%	+127.32%
RLMD Relmada Therapeutics	+1.22%	+9.31%	+4.54%	-7.23%	-75.39%
ULUR ULURU	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAB BioAtla	2.4443 of 5 stars	3.0	3.0	0.0	0.0	2.2	2.5	0.6
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	4.6376 of 5 stars	3.1	5.0	0.0	4.4	3.8	2.5	0.6
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAB BioAtla	2.00	Hold	$5.00	1,082.03% Upside
OTLC Oncotelic Therapeutics	0.00	N/A	N/A	N/A
RLMD Relmada Therapeutics	2.25	Hold	$5.00	545.99% Upside
ULUR ULURU	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ULUR, BCAB, RLMD, and OTLC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/13/2025	BCAB BioAtla	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
8/13/2025	BCAB BioAtla	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAB BioAtla	$11M	2.26	N/A	N/A	($0.29) per share	-1.46
OTLC Oncotelic Therapeutics	$70K	310.07	$0.01 per share	9.76	$0.02 per share	2.65
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$0.48 per share	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAB BioAtla	-$69.78M	-$1.10	N/A	N/A	N/A	N/A	-1,177.18%	-137.51%	11/6/2025 (Estimated)
OTLC Oncotelic Therapeutics	-$4.52M	-$0.01	N/A	∞	N/A	N/A	-9.62%	-2.72%	N/A
RLMD Relmada Therapeutics	-$79.98M	-$2.22	N/A	N/A	N/A	N/A	-223.17%	-180.41%	11/6/2025 (Estimated)
ULUR ULURU	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest ULUR, BCAB, RLMD, and OTLC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	BCAB BioAtla	-$0.29	-$0.31	-$0.02	-$0.32	N/A	N/A
8/7/2025	Q2 2025	RLMD Relmada Therapeutics	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAB BioAtla	N/A	1.24	1.24
OTLC Oncotelic Therapeutics	N/A	0.01	0.01
RLMD Relmada Therapeutics	N/A	4.11	4.11
ULUR ULURU	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAB BioAtla	77.23%
OTLC Oncotelic Therapeutics	N/A
RLMD Relmada Therapeutics	45.24%
ULUR ULURU	N/A

Insider Ownership

Company	Insider Ownership
BCAB BioAtla	11.22%
OTLC Oncotelic Therapeutics	39.22%
RLMD Relmada Therapeutics	20.70%
ULUR ULURU	1.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAB BioAtla	60	58.72 million	52.13 million	Optionable
OTLC Oncotelic Therapeutics	20	409.52 million	248.91 million	Not Optionable
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable
ULUR ULURU	2	30.57 million	30.24 million	Not Optionable

ULUR, BCAB, RLMD, and OTLC Headlines

Recent News About These Companies

YouTubers Find Out Uluru's Rules Are No Joke

August 27 at 5:40 AM | msn.com

Onboard Qantas’ Brand New A220 Over the Australian Outback

August 26 at 7:39 PM | msn.com

‘Not an attractive destination’: Couple films Uluru, commits ’20 fineable offences’

August 26 at 7:39 PM | msn.com

Tourists shocked when ordered to delete photos of oft-visited area — and they could have faced a hefty fine: ‘We weren’t aware about that’

August 25 at 9:51 PM | msn.com

‘20 fineable offences’: Aussie couple’s shock email three months after Uluru trip

August 25 at 9:51 PM | news.com.auN

Travel vloggers given ’20 fines’ after filming during visit to historic world site – how you can avoid the same mistake

August 25 at 9:51 PM | thesun.co.uk

Uluru tourists ordered to delete photos of sacred sites - and they could have faced a hefty fine: ‘We weren’t aware about that’

August 25 at 9:51 PM | skynews.com.auS

Virgin Australia & Starlight Foundation Celebrate 15 Years Of Partnership In The Heart Of Australia

August 21, 2025 | bandt.com.auB

Starlight Children’s Foundation and Virgin Australia mark 15 years of granting wishes

August 20, 2025 | travelweekly.com.auT

Starlight Foundation grants ‘unique Uluru experience’ to bring joy ...

August 20, 2025 | themercury.com.auT

Starlight Foundation grants ‘unique Uluru experience’ to bring joy lil battler following tough diagnosis

August 18, 2025 | ntnews.com.auN

Douglas Crabbe, sentenced to life for Uluru mass murder, has latest parole bid rejected

August 16, 2025 | ntnews.com.auN

Uluru truck mass murderer Douglas Crabbe's parole bid rejected in WA

August 14, 2025 | msn.com

Uluru 1Q Net Y192.00M Vs Net Y48.00M

August 14, 2025 | marketwatch.com

Elder likens algal bloom devastation to watching Uluru being destroyed

August 13, 2025 | msn.com

Finding the ‘copper coloured mountain’: Why Kung Fu nuns and more are on a pilgrimage to Uluru

August 12, 2025 | townsvillebulletin.com.auT

The measure of success: How Australia can become a long-term civilisation

August 12, 2025 | abc.net.auA

Australian swim sensation Kaylee McKeown reveals romance with ex-AFL player Declan Watson

August 11, 2025 | news.com.auN

From Melbourne to Darwin: A 17-day journey through Australia’s spiritual heartland

August 6, 2025 | neoskosmos.comN

Busy tourist season at Uluru equating to stronger NITA trainee outcomes

August 6, 2025 | ntnews.com.auN

New MarketBeat Followers Over Time

Media Sentiment Over Time

ULUR, BCAB, RLMD, and OTLC Company Descriptions

BioAtla NASDAQ:BCAB

$0.42 -0.02 (-5.33%)

As of 03:40 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Oncotelic Therapeutics OTCMKTS:OTLC

$0.05 +0.01 (+13.73%)

As of 03:03 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Relmada Therapeutics NASDAQ:RLMD

$0.77 +0.10 (+15.61%)

As of 03:41 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time